Jurjen S. Lagas

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jurjen S. Lagas, Robert A.B. van Waterschoot, Rolf W. Sparidans et al. · Molecular Cancer Therapeutics · 2010 · 182 citations

Medicine, Pharmacokinetics, Pharmacology +17

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jurjen S. Lagas, Robert A.B. van Waterschoot, Vicky A.C.J. van Tilburg et al. · Clinical Cancer Research · 2009 · 173 citations

Medicine, Pharmacokinetics, Pharmacology +16

Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

Seng Chuan Tang, Jurjen S. Lagas, Nienke A. G. Lankheet et al. · International Journal of Cancer · 2011 · 159 citations

Medicine, Pharmacokinetics, Pharmacology +17

Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

Maria L.H. Vlaming, Karin Mohrmann, Els Wagenaar et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 155 citations

Medicine, Biochemistry, Pharmacology +17

Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes

Robert A.B. van Waterschoot, Antonius E. van Herwaarden, Jurjen S. Lagas et al. · Molecular Pharmacology · 2007 · 113 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13